EXTON, Pa., Dec 01, 2011 – Fibrocell Science, Inc. (OTCBB:FCSC.OB), a biotechnology company focused on the development of autologous (personalized) cell therapies for aesthetic, medical and scientific applications, announced today that David Pernock, the Company’s Chairman and CEO, will be presenting at the Oppenheimer 22nd Annual Healthcare Conference to be held on December 13-14, 2011 at the Waldorf=Astoria in New York City.

Fibrocell’s presentation is scheduled for Wednesday, December 14, 2011 at 11:25 AM Eastern Time.

The presentation will be webcast live, and a replay will be available on the Investors section of the Company’s website at www.fibrocellscience.com.

About Fibrocell Science, Inc.

Fibrocell Science, Inc. (OTCBB: FCSC) is a biotechnology company focused on the development of regenerative cell therapy for aesthetic, medical and scientific applications. Fibrocell Science is committed to advancing the scientific, medical and commercial potential of autologous skin and tissue, as well as its innovative cellular processing technology and manufacturing excellence. For additional information, please visit www.fibrocellscience.com.

CONTACTS:

Media
Marina Maher Communications
Jessica Morrison
(212) 485-6806
jmorrison@mahercomm.com

Investors
ICR, LLC
Sherry Bertner
(646) 277-1247
sherry.bertner@icrinc.com